This article provides a general overview of the semiconductor industry's trends and outlook, without reporting on a specific new development or concrete event.
This collaboration positions a needle-free, patch-based vaccine for entry into the European market, potentially altering vaccine administration standards. The technology's room-temperature stability could resolve complex cold-chain logistics, expanding vaccine access in remote or underserved regions globally and improving pandemic preparedness.
SK Bioscience joins a consortium with IDT Biologika and Vaxxas for an EU-funded vaccine project
The project will develop a needle-free influenza vaccine using Vaxxas's HD-MAP technology
The vaccine aims for easier administration, lower antigen dosage, and improved room-temperature stability
The project will develop a needle-free influenza vaccine using Vaxxas's HD-MAP technology
IDT Biologika will lead the project and manage European manufacturing, with SK Bioscience supplying the drug substance
Sign in to save notes on signals.
Sign In